Tyrosine kinase inhibitors and drug interactions: A review with practical recommendations

Clinical and Translational Oncology

Volumn 14, Issue 2, 2012, Pages 94-101

  Pajares, Bella ^a   Torres, Esperanza ^a   Trigo, José Manuel ^a   Sáez, María Isabel ^a   Ribelles, Nuria ^a   Jiménez, Begoña ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

CYP; Drug interactions; Pharmacodynamic; Pharmacokinetic; Tyrosine kinase inhibitors

Indexed keywords

AMMONIUM HYDROXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; MAGNESIUM; N DEETHYLSUNITINIB; NEOMYCIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SORAFENIB; SUNITINIB; UNINDEXED DRUG;

AGE; AREA UNDER THE CURVE; COMORBIDITY; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GENETIC VARIABILITY; GRAPE JUICE; HUMAN; HYPERTENSION; LIVER METABOLISM; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE;

ANIMALS; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84860781566     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0767-5     Document Type: Review

References (61)

1. Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 19:1147-1151 (Pubitemid 32176292)
2. Riechelmann RP, Tannock IF, Wang L et al (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592-600 (Pubitemid 47073540)
3. Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373 (Pubitemid 46450424)
4. Desar IM, Burger DM, Van Hoesel QG et al (2009) Pharmacokinetics of sunitinib in an obese patient with a GIST. Ann Oncol 20:599-600
5. Bello CL, Sherman L, Zhou J et al (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358
6. Moore M, Hirte HW, Siu L et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16:1688-1694 (Pubitemid 41510145)
7. Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437 (Pubitemid 46698720)
8. Rini BI (2006) Sorafenib. Expert Opin Pharmacother 7:453-461 (Pubitemid 43379611)
9. FDA (2009) Drug label Nexavar approved 12/20/2005. http://www.accessdata. fda.gov/ scripts/cder/drugsatfda/. Accessed on 02.03.2009
10. Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30:1426-1447
11. Bence AK, Anderson EB, Halepota MA et al (2005) Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23:39-49 (Pubitemid 39505950)
12. Burris HA 3rd (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9[Suppl 3]:10-15
13. Reckmann AH, Fischer T, Peng B et al (2001) Effect of food on STI571 Glivec pharmacokinetics and bioavailability. Proc Am Soc Clin Oncol 20:abstract 1223
14. Sparano BA, Egorin MJ, Parise RA et al (2009) Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63:525-528
15. Ling J, Fettner S, Lum BL et al (2008) Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 19:209-216
16. FDA (2010) Drug label Erlotinib approved 15.09.2005. http://www. accessdata.fda.gov/drugsatfda/. Accessed on 16.09.2010
17. Swaisland H, Laight A, Stafford L et al (2001) Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 40:297-306 (Pubitemid 32458155)
18. Swaisland HC, Smith RP, Laight A et al (2005) Single-dose clinical pharmacokinetic studies of gefi tinib. Clin Pharmacokinet 44:1165-1177 (Pubitemid 41483701)
19. Cohen MH, Williams GA, Sridhara R et al (2004) United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218 (Pubitemid 38365209)
20. FDA (2010) Drug label Gefitinib approved 05.05.2003. http://www. accessdata.fda.gov/drugsatfda/. Accessed on 16.09.2010
21. Wester MR, Johnson EF, Marques-Soares C et al (2003) Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fi t model of substrate binding. Biochemistry 42:9335-9345 (Pubitemid 36959241)
22. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258 (Pubitemid 27122521)
23. Blower P, de Wit R, Goodin S, Aapro M (2005) Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 55:117-142 (Pubitemid 40981915)
24. Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144-160 (Pubitemid 24064238)
25. Gibbs MA, Hosea NA (2003) Factors affecting the clinical development of cytochrome p450 3A substrates. Clin Pharmacokinet 42:969-984 (Pubitemid 37056104)
26. Fuhr U (2000) Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 38:493-504 (Pubitemid 30394314)
27. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448 (Pubitemid 34311090)
28. Aubert RE, Stanek EJ, Yao J et al (2009) Risk of breast cancer recurrence in women initiating tamoxifen with CYP 2D6 inhibitors. J Clin Oncol 27[18 S]:abstr CRA508
29. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202 (Pubitemid 29017140)
30. Evans WE, McLeod HL (2003) Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 348:538-549 (Pubitemid 36159890)
31. Phillips KA, Veenstra DL, Oren E et al (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279 (Pubitemid 33063150)
32. Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 18:837-851 (Pubitemid 34073129)
33. FDA (2010) Drug label Sunitinib approved 2006. http://www.accessdata.fda. gov/drugsatfda/. Accessed on 16.09.2010
34. Bello C, Houk B, Sherman L et al (2005) Effect of rifampicin on the pharmacokinetics of SU 11248 in healthy volunteers. J Clin Oncol 23[16 S]:3078
35. Washington C, Eli M, Bello C et al (2003) The effect of ketoconazole a potent CYP 3 A4 inhibitor on SU 011248 pharmacokinetics in Caucasian and Asian healthy subjects. Proc Am Soc Clin Oncol 22:abstr 553
36. Kane RC, Farrell AT, Saber H et al (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278 (Pubitemid 46095398)
37. Lathia C, Lettieri J, Cihon F et al (2006) Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57:685-692
38. FDA (2010) Drug label Lapatinib approved 2007. http://www.accessdata.fda. gov/drugsatfda/. Accessed on 16.09.2010
39. Smith DA, Koch KM, Arya N et al (2009) Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 67:421-426
40. Pursche S, Schleyer E, von Bonin M et al (2008) Infl uence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 3:198-203
41. Bolton AE, Peng B, Hubert M et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102-106 (Pubitemid 38186987)
42. Smith PF, Bullock JM, Booker BM et al (2004) Induction of imatinib metabolism by hypericum perforatum. Blood 104:1229-1230 (Pubitemid 39038051)
43. Cutreix C, Peng B, Mehring G (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294 (Pubitemid 39304422)
44. van Erp NP, Gelderblom H, Karlsson MO et al (2007) Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13:7394-7400
45. Oostendorp RL, Buckle T, Beijnen JH et al (2009) The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40
46. O'Brien SG, Meinhardt P, Bond E et al (2003) Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89:1855-1859 (Pubitemid 37533259)
47. Wang Y, Zhou L, Dutreix C et al (2008) Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 65:885-892 (Pubitemid 351677440)
48. FDA (2010) Drug label Imatinib approved 2003. http://www.accessdata.fda. gov/drugsatfda/. Accessed on 16.09.2010
49. Johnson JR, Cohen M, Sridhara R et al (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414-6421 (Pubitemid 41338977)
50. Lu JF, Eppler SM, Wolf J et al (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80:136-145 (Pubitemid 44160689)
51. Li J, Zhao M, He P et al (2007) Differential metabolism of gefi tinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737 (Pubitemid 46955138)
52. Hamilton M, Wolf JL, Rusk J et al (2006) Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12:2166-2171
53. Rakhit A, Pantze MP, Fettner S et al (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (Sim- CYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64:31-41
54. Yamamoto N, Horiike A, Fujisaka Y et al (2008) Phase I dose-fi nding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496 (Pubitemid 350275984)
55. Grenader T, Gipps M, Shavit L, Gabizon A (2007) Signifi cant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer 57:404-406 (Pubitemid 47285413)
56. Veeraputhiran M, Sundermeyer M (2008) Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 9:232-234
57. Swaisland HC, Ranson M, Smith RP et al (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081 (Pubitemid 41356392)
58. McKillop D, Partridge EA, Kemp JV et al (2005) Tumor penetration of gefi tinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4:641-649 (Pubitemid 40601846)
59. Burris HA 3rd, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313 (Pubitemid 46206984)
60. Clark JW, Eder JP, Ryan D et al (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480 (Pubitemid 41060823)
61. Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279 (Pubitemid 32591445)